Allianz Asset Management GmbH lifted its position in Imperva Inc (NASDAQ:IMPV) by 58.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,149 shares of the software maker’s stock after purchasing an additional 21,732 shares during the period. Allianz Asset Management GmbH owned about 0.17% of Imperva worth $2,567,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Imperva in the 3rd quarter valued at $134,000. First Quadrant L P CA acquired a new position in shares of Imperva in the 3rd quarter valued at $136,000. Ameritas Investment Partners Inc. lifted its stake in shares of Imperva by 18.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,940 shares of the software maker’s stock valued at $141,000 after purchasing an additional 464 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Imperva by 26.2% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock valued at $201,000 after purchasing an additional 866 shares during the period. Finally, Amalgamated Bank acquired a new position in shares of Imperva in the 2nd quarter valued at $206,000. Hedge funds and other institutional investors own 96.93% of the company’s stock.
Several equities analysts recently issued reports on IMPV shares. Morgan Stanley reiterated an “underweight” rating and issued a $39.00 target price on shares of Imperva in a research note on Thursday, November 9th. Evercore ISI restated a “buy” rating and set a $56.00 price objective on shares of Imperva in a research report on Wednesday, November 8th. Wells Fargo & Co cut shares of Imperva from an “outperform” rating to a “market perform” rating in a research report on Monday, October 9th. Piper Jaffray Companies restated a “neutral” rating and set a $58.00 price objective on shares of Imperva in a research report on Friday, October 13th. Finally, Zacks Investment Research upgraded shares of Imperva from a “hold” rating to a “strong-buy” rating and set a $50.00 price objective for the company in a research report on Tuesday, October 24th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Imperva presently has a consensus rating of “Hold” and a consensus target price of $51.86.
Imperva (NASDAQ:IMPV) last issued its earnings results on Wednesday, November 8th. The software maker reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.11. The business had revenue of $83.89 million during the quarter, compared to analysts’ expectations of $83.79 million. Imperva had a net margin of 3.04% and a negative return on equity of 8.52%. The company’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.08 earnings per share. research analysts expect that Imperva Inc will post -0.52 EPS for the current fiscal year.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Want to see what other hedge funds are holding IMPV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imperva Inc (NASDAQ:IMPV).
What are top analysts saying about Imperva? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Imperva and related companies.